ABVC BioPharma (ABVC) Proxy filing summary

Executive summary

• Special meeting scheduled for October 8, 2026, to be held virtually for shareholder participation and efficiency.

• Three key proposals: approval of 2026 Equity Incentive Plan, ratification of equity awards since February 16, 2026, and authorization to issue shares for land acquisitions in Taiwan.

• Board unanimously recommends voting in favor of all proposals.

• Record date for voting eligibility is September 14, 2026; each share has one vote.

Voting matters and shareholder proposals

• Proposal 1: Approve the 2026 Equity Incentive Plan, replacing the 2016 Plan, with a new formula for share pool and annual evergreen provision.

• Proposal 2: Ratify equity awards (600,000 shares) granted to two advisors since February 16, 2026, pending approval of the new plan.

• Proposal 3: Authorize issuance of up to 1,600,653 shares at no less than $1.00 per share for acquisition of land in Taoyuan and Hualien, Taiwan, to comply with Nasdaq rules.

• All proposals require a majority of votes cast for approval.

Board of directors and corporate governance

• Board members, including Ms. Shuling Jiang, are involved in related-party transactions and subject to audit committee review.

• Board retains authority to determine final terms of land acquisition and share issuance.